Typhoid [strain salmonella typhi Ty21a] vaccine DR is a Live Attenuated Vaccine owned by Emergent BioSolutions, and is involved in 1 clinical trial, which was completed.

Typhoid Vaccine Live Oral Ty21a works by stimulating the immune system of the person who receives the vaccine to make their own protective antibodies against this disease. Vivotif, composed of components of pathogen prevents the disease by evoking a local immune response in the intestinal tract. The local immunity is induced by oral ingestion of a live attenuated strain of S. typhi undergoing an aborted infection. The ability of S. typhi to cause disease and to induce a protective immune response is dependent upon the bacteria possessing a complete lipopolysaccharide. The S. typhi Ty21a vaccine strain, by virtue of a reduction in enzymes essential for lipopolysaccharide biosynthesis, is restricted in its ability to produce complete lipopolysaccharide. However, a sufficient quantity of complete lipopolysaccharide is synthesized to evoke a protective immune response. Despite low levels of lipopolysaccharide synthesis, the cells lyse before regaining a virulent phenotype due to the intracellular build-up of intermediates during lipopolysaccharide synthesis.

The revenue for Typhoid [strain salmonella typhi Ty21a] vaccine DR is expected to reach a total of $959m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Typhoid [strain salmonella typhi Ty21a] vaccine DR NPV Report.

Typhoid [strain salmonella typhi Ty21a] vaccine DR is currently owned by Emergent BioSolutions.

Typhoid [strain salmonella typhi Ty21a] vaccine DR Overview

Typhoid Vaccine Live Oral Ty21a (Vivotif, Vivotif L, Typhoral) is an immunizing agent. It is formulated as delayed release hard gelatin capsule and powder for oral route of administration. Vivotif is indicated for immunization of adults and children greater than 6 years of age against typhoid fever caused by Salmonella typhi.

Emergent BioSolutions Overview

Emergent BioSolutions (Emergent) is a life sciences company that provides specialized products to address medical needs and public health threats (PHTs). Its solutions help address PHTs including chemical, biological, radiological, nuclear and explosives (CBRNE), emerging infectious diseases, travel health, emerging health crises, and acute/emergency care. It offers vaccines, therapeutics, drug-device combination products, and contract development and manufacturing services. Emergent‘s pipeline candidates target dengue and other influenza infections. It also offers specialized products to governments and commercial customers. The company distributes its products in the US and Canada through its commercial sales forces and third-party distributors. Emergent is headquartered in Rockville, Maryland, the US.

The company reported revenues of (US Dollars) US$1,792.7 million for the fiscal year ended December 2021 (FY2021), an increase of 15.3% over FY2020. In FY2021, the company’s operating margin was 19.7%, compared to an operating margin of 27.9% in FY2020. In FY2021, the company recorded a net margin of 12.9%, compared to a net margin of 19.6% in FY2020. The company reported revenues of US$240 million for the third quarter ended September 2022, a decrease of 1.1% over the previous quarter.

Quick View – Typhoid [strain salmonella typhi Ty21a] vaccine DR

Report Segments
  • Innovator (NME)
Drug Name
  • Typhoid [strain salmonella typhi Ty21a] vaccine DR
Administration Pathway
  • Oral
Therapeutic Areas
  • Infectious Disease
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.